Navigation Links
Gene Found Activated in 70% of Prostate Cancer Cases, George Washington University Medical Center Scientists Report
Date:10/24/2008

DRS. PATRICIA BERG AND ARNOLD SCHWARTZ LED TEAM, Article in Modern Pathology set for print publication January 2009

BERG HAD ALSO DISCOVERED SAME GENE'S ACTIVATION IN MAJORITY OF BREAST CANCER CASES

WASHINGTON, Oct. 24 /PRNewswire-USNewswire/ -- A gene has been found activated in 70% of prostate cancer tumors, the same gene that has been discovered activated in a majority of breast cancer cases, report scientists at the George Washington University Medical Center led by Dr. Patricia Berg, who discovered and cloned the gene, and Dr. Arnold Schwartz. Berg is Professor of Molecular Biology and Biochemistry and directs a laboratory at George Washington University Medical Center in Washington, DC, and Schwartz is Professor of Pathology and practicing clinician at GWUMC.

In the January, 2009 print issue of Modern Pathology, a journal of the Nature Publishing Group, the team of researchers led by Berg and Schwartz will report that "Significant BP1 immunoreactivity was identified in approximately 70% of prostatic adenocarcinomas, whether the analysis was performed on tissue sections (50 cases) or tissue microarray platforms (123 cases)." The findings compare to "less than 5%" BP1 activity in normal cells. The researchers conclude that "These findings suggest that BP1 is an important upstream factor in the carcinogenic pathway of prostate cancer and that the expression of BP1 may reflect or directly contribute to tumor progression and/or invasion."

In addition to Berg and Schwartz, the team of authors includes Drs. Yan-Gao Man, Department of Gynecologic and Breast Pathology, The Armed Forces Institute of Pathology, Washington DC; M Katayoon Rezaei, Department of Pathology, The George Washington University Medical Center, Washington DC; and Samuel J Simmens, Department of Biostatistics, The George Washington University Medical Center, Washington DC.

Berg had previously published and reported, and the authors cite in the current article, that BP1 is activated in a majority of breast cancer (80%) and acute myeloid leukemia (63%) cases. The authors say, "Our current and past findings suggest that BP1 may be an important regulatory factor in the oncogenic pathway of several malignancies including prostate cancer." Berg stated today, "BP1 is a new, potentially significant target for therapy. It could be an important new diagnostic marker for prostate cancer and the other cancers in which it is expressed."

Prostate cancer is the leading cancer among men. The National Cancer Institute estimates 186,320 new cases and 28,660 deaths from prostate cancer in the U.S. in 2008.

The article is titled, "BP1, a homeoprotein, is significantly expressed in prostate adenocarcinoma and is concordant with prostatic intraepithelial neoplasia." The article is also available as "advance online publication" (Citation: Modern Pathology advance online publication 17 October 2008; doi: 10.1038/modpathol.2008.168).

Link to abstract: http://www.nature.com/doifinder/10.1038/modpathol.2008.168.

CONTACT: Dr. Berg/GWUMC: Robert Weiner Associates, +1-301-283-0821, +1-202-329-1700, Modern Pathology: Marsha Cline, +1-317-274-2476


'/>"/>
SOURCE Dr. Patricia Berg of GWUMC/Robert Weiner Associates
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Local Research Foundation Achieves Milestone in Fight Against Cancer
2. Michael J. Fox Foundation Awards $2 Million for Research on Cognitive and Mood Symptoms of Parkinsons Disease
3. New Genes Found for Inflammatory Bowel Disease in Children
4. SF1126, Semafores PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines
5. Gene That Causes Childhood Cancer Neuroblastoma Is Found
6. Alzheimers Foundation of America Survey: Americans With Memory Concerns Fall Short of Talking to Doctors
7. Michael J. Fox Foundation Funds $1.1 Million for Cutting-Edge Approaches to Parkinsons Disease Under Rapid Response Innovation Awards 2008
8. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
9. Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinsons Disease
10. PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124
11. Childrens Brain Tumor Foundations Tissue Bank Consortium May Solve Dire Problem in Pediatric Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... India , April 19, 2017 ... and Application, Forecast to 2022 report has covered and analysed ... statistics and information on market size, shares and growth factors. ... major drivers, challenges and opportunities in the global market. ... Browse 152 Tables and Figures, ...
(Date:4/19/2017)... Companion animal vaccines ... pets such as canine, avian and feline. ... such as Attenuated Live Vaccines, Conjugate Vaccines, Inactivated ... Recombinant Vaccines. Attenuated live vaccines are derived from ... have been weakend under laboratory conditions. Conjugate vaccines ...
(Date:4/19/2017)... , April 19, 2017  Novartis today ... the National Heart, Lung, and Blood Institute (NHLBI) ... that 58% of patients with treatment-naïve severe aplastic ... when treated with eltrombopag at the initiation of ... The study evaluated three sequential treatment groups, or ...
Breaking Medicine Technology:
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... a breakthrough topical cream that’s the first in a new class of photodynamic ... the overall appearance of skin, visibly reduce outward signs of aging, and minimize ...
(Date:4/25/2017)... ... April 25, 2017 , ... As President Trump challenges ... for how his administration could impact the employee benefits industry. James Slotnick, AVP, ... most likely to make it through Congress. His discussion will focus on the ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... rely on contracted partners to help with process innovation in drug formulation and ... formulation experience along with state-of-the-art analytical equipment in support of their development and ...
(Date:4/25/2017)... ... April 25, 2017 , ... Somnoware, a ... its patient care management module. Using this new feature, sleep physicians can now ... initiated on continuous positive airway pressure (CPAP), oral, or other forms of sleep ...
(Date:4/24/2017)... ... April 24, 2017 , ... Emmanuel College is introducing ... advance their careers. Beginning in the fall of 2017, Emmanuel’s program will allow registered ... few as 16 months and for as little as $14,528. These changes will enable ...
Breaking Medicine News(10 mins):